Loading…
Loading…
CSA (VictoryShares US Small Cap Volatility Wtd ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how CSA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CSA and 80,000+ other tickers.
The VictoryShares US Small Cap Volatility Wtd ETF provides investors with exposure to smaller American companies, designed to circumvent the common drawbacks of traditional market-capitalization weighting schemes. Its primary aim is to mirror the investment returns of the Nasdaq Victory US Small Cap 500 Volatility Weighted Index, prior to accounting for fees and expenses. This objective is realized through a distinct Volatility Weighting Methodology, which integrates both fundamental company criteria and volatility-based weighting in an effort to outperform conventional cap-weighted indexing strategies.
BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), the leader in smart home security solutions, today announced it has joined the Board of Directors of the Connectivity Standards Alliance (CSA), the global organization behind Matter, Zigbee and Aliro, foundational standards shaping the future of connected living.
Demonstration validates Matter readiness for commercial buildings, smart homes and next-generation IoT deployments using concurrent multiprotocol technology AUSTIN, Texas, June 16, 2026 /PRNewswire/ -- Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless connectivity, today announced the successful deployment and operation of a 200-node Matter-over-Thread validation network, demonstrating the scalability, reliability and performance of Matter for large-scale smart building, commercial IoT and next-generation smart home applications. Announced at the Connectivity Standards Alliance's (CSA) inaugural Unify event, this highlights a key evolution in the Matter ecosystem: the industry is moving beyond proving interoperability and toward demonstrating scalability for real-world deployments.
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with no approved FDA-approved targeted therapies Dual-Purpose Synergy - Planned Phase 2a proof-of-concept trial expected to generate safety, renal injury signals, and 12-LOX pathway biology in high-risk cardiac surgery patients, while generating high-value data potentially relevant to the Company's lead HIT indication Capital-Efficient Development: Leverages shared in-hospital ICU infrastructure and an intravenous (IV) formulation to offer a turnkey critical care franchise for a global pharmaceutical partner Maximizes 12-LOX Platform Valuation – Strongly positioned for upcoming strategic collaboration and licensing meetings at BIO 2026 PONTE VEDRA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced that it plans to initiate a Phase 2a proof-of-concept clinical trial of its lead drug candidate, CAD-1005, being studied to prevent Acute Kidney Injury (AKI) in high-risk patients undergoing cardiac surgery.
Acer Listed on 2026 Dow Jones Best-in-Class World Index PR Newswire TAIPEI, June 10, 2026
Fosun International Included in S&P Global Sustainability Yearbook (China Edition) 2026, Maintains Top 1% Ranking for Third Consecutive Year